Rudolf Kwan Athenex, Inc. (ATNX) insider trading activity

Rudolf Kwan is EVP, Chief Medical Officer of Athenex, Inc.. Currently has a direct ownership of 49,816 shares of ATNX, which is worth approximately $498. The most recent transaction as insider was on May 05, 2023, when has been sold 3,603 shares (Common Stock) at a price of $1.36 per share, resulting in proceeds of $4,900. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 49.8K

0% 3M change

0% 12M change

Total Value Held $498

Rudolf Kwan Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
May 05 2023	BUY Grant, award, or other acquisition	$4,900 $1.36 p/Share	3,603 Added 6.74%	49,816 Common Stock
Apr 21 2023	BUY Grant, award, or other acquisition	$4,881 $1.3 p/Share	3,755 Added 7.51%	46,213 Common Stock
Apr 07 2023	BUY Grant, award, or other acquisition	$4,900 $1.22 p/Share	4,017 Added 8.64%	42,458 Common Stock
Mar 24 2023	BUY Grant, award, or other acquisition	$4,899 $1.39 p/Share	3,525 Added 8.4%	38,441 Common Stock
Mar 10 2023	BUY Grant, award, or other acquisition	$4,900 $1.94 p/Share	2,526 Added 6.75%	34,916 Common Stock
Feb 24 2023	BUY Grant, award, or other acquisition	$4,899 $2.74 p/Share	1,788 Added 5.23%	32,390 Common Stock
Feb 10 2023	BUY Grant, award, or other acquisition	$4,791 $0.22 p/Share	21,778 Added 3.44%	612,024 Common Stock
Jan 27 2023	BUY Grant, award, or other acquisition	$4,811 $0.19 p/Share	25,323 Added 4.11%	590,246 Common Stock
Jan 13 2023	BUY Grant, award, or other acquisition	$5,005 $0.19 p/Share	26,344 Added 4.46%	564,923 Common Stock
Dec 30 2022	BUY Grant, award, or other acquisition	$4,983 $0.15 p/Share	33,220 Added 5.81%	538,579 Common Stock
Dec 16 2022	BUY Grant, award, or other acquisition	$4,966 $0.12 p/Share	41,386 Added 7.57%	505,356 Common Stock
Dec 02 2022	BUY Grant, award, or other acquisition	$4,924 $0.2 p/Share	24,623 Added 5.04%	463,970 Common Stock
Nov 18 2022	BUY Grant, award, or other acquisition	$4,798 $0.19 p/Share	25,257 Added 5.44%	439,347 Common Stock
Nov 04 2022	BUY Grant, award, or other acquisition	$5,020 $0.2 p/Share	25,103 Added 5.72%	414,090 Common Stock
Oct 21 2022	BUY Grant, award, or other acquisition	$4,846 $0.18 p/Share	26,923 Added 6.47%	388,987 Common Stock
Oct 07 2022	BUY Grant, award, or other acquisition	$4,882 $0.24 p/Share	20,340 Added 5.32%	362,064 Common Stock
Sep 23 2022	BUY Grant, award, or other acquisition	$4,880 $0.24 p/Share	20,333 Added 5.62%	341,724 Common Stock
Sep 09 2022	BUY Grant, award, or other acquisition	$4,863 $0.46 p/Share	10,572 Added 3.18%	321,391 Common Stock
Aug 26 2022	BUY Grant, award, or other acquisition	$4,863 $0.47 p/Share	10,346 Added 3.22%	310,819 Common Stock
Aug 12 2022	BUY Grant, award, or other acquisition	$4,900 $0.52 p/Share	9,423 Added 3.04%	300,473 Common Stock
Aug 03 2022	SELL Payment of exercise price or tax liability	$2,472 $0.58 p/Share	4,262 Reduced 1.44%	291,050 Common Stock
Aug 03 2022	BUY Exercise of conversion of derivative security	-	17,500 Added 5.59%	295,312 Common Stock
Jul 15 2022	BUY Grant, award, or other acquisition	$4,871 $0.59 p/Share	8,256 Added 2.99%	268,147 Common Stock
Jul 09 2022	BUY Grant, award, or other acquisition	$4,929 $0.51 p/Share	9,665 Added 3.36%	277,812 Common Stock
Jul 01 2022	BUY Grant, award, or other acquisition	$4,866 $0.43 p/Share	11,316 Added 4.17%	259,891 Common Stock

Rudolf Kwan

EVP, Chief Medical Officer

Buffalo, NY

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ATNX shares.

Notify only if

Value

Insider Trading

Get notified when an Athenex, Inc. insider buys or sells ATNX shares.

Notify only if

Operation

Value

Type

News

Receive news related to Athenex, Inc.

Track Activities on ATNX

Account